Vaxcyte, Inc. (PCVX) Revenue History
Annual and quarterly revenue from 2017 to present
PCVX Revenue Over Time (2017–2025)
PCVX Revenue Growth History
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Revenue Breakdown (FY 2021)
PCVX's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
PCVX Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 23, 2026, Vaxcyte, Inc. (PCVX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
PCVX's historical revenue data shows various trends over time.
Revenue by Segment
PCVX's revenue is primarily driven by Pneumococcal Conjugate Vaccine (100%). With over half of revenue concentrated in Pneumococcal Conjugate Vaccine, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including PFE (+1.4% YoY), MRK (+1.2% YoY), and GSK (+5.4% YoY). Compare PCVX vs PFE →
PCVX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PCVXCurrent | $0 | - | - | - | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 MRK | $64.9B | +1.2% | +9.4% | 36.2% | |
 GSK | $32.7B | +5.4% | +6.0% | 25.5% | |
 SNY | $46.7B | +14.1% | +4.6% | 13.6% | |
 BNTX | $2.8B | +4.0% | +41.7% | -22.6% |
PCVX Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-923,675,000 | - |
| 2024 | $0 | - | $0 | - | $-569,546,000 | - |
| 2023 | $0 | - | $0 | - | $-468,041,000 | - |
| 2022 | $0 | - | $0 | - | $-232,256,000 | - |
| 2021 | $0 | - | $0 | - | $-103,670,000 | - |
| 2020 | $0 | - | $-1,405,000 | - | $-89,581,000 | - |
| 2019 | $0 | - | $-1,232,000 | - | $-54,153,000 | - |
| 2018 | $0 | - | $-1,037,000 | - | $-35,533,000 | - |
| 2017 | $0 | - | $0 | - | $-17,833,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PCVX — Frequently Asked Questions
Quick answers to the most common questions about buying PCVX stock.
Is PCVX's revenue growth accelerating or slowing?
PCVX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is PCVX's revenue history from 2017 to 2026?
Vaxcyte, Inc. (PCVX) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is PCVX's long-term revenue growth rate (CAGR)?
Vaxcyte, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for PCVX.
Why does PCVX's quarterly revenue fluctuate?
PCVX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Vaxcyte, Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is PCVX's revenue distributed by segment?
PCVX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does PCVX's revenue compare to industry peers?
Vaxcyte, Inc. (PCVX) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.